Influenza Clinical Trial
Official title:
Clinical Study to Compare the Immune Response of Half Dose Trivalent Inactivated Influenza Vaccine (TIV) to Full Dose
NCT number | NCT00283283 |
Other study ID # | A-13205 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | November 2004 |
Est. completion date | May 2006 |
Verified date | February 2021 |
Source | U.S. Army Medical Research and Development Command |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study compared full-dose Flu vaccine to half-dose Flu-vaccine during the 2004-2005 flu season.
Status | Completed |
Enrollment | 1316 |
Est. completion date | May 2006 |
Est. primary completion date | November 2004 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: - Able to understand and comply with all study procedures including availability for all study visits and follow up surveys within 6 months following study enrollment. - DEERS eligible beneficiaries eligible for influenza vaccination and able to give informed consent. - Age 18-49 - Patients presenting to travel clinic with no exclusion criteria; - Household contacts and out-of-home caretakers of infants from 6-23 months of age; - Hospital and/or employees providing service to the public who are not eligible for the post-October 5th recommendations for priority immunization; - DOD employees eligible for influenza vaccination prior to October 5th but excluded in the post October 5th guidelines; - People living in dormitories or under other crowded conditions, to prevent outbreaks; - Ages 50-64 years of age who are not eligible for the post-October 5th recommendations for priority immunization and with no standard of care contraindications to vaccination. - Eligible in the Department of Defense for influenza vaccination Exclusion Criteria: - all children aged < 18 years (includes children aged 6 months-18 years on chronic aspirin therapy); - adults aged >65 years; - persons aged 2-64 years with underlying chronic medical conditions: - includes persons with chronic cardiac or pulmonary disease, diabetes mellitus, hemoglobinopathy, or immunosuppressive illness; - any acute or chronic condition that, in the opinion of the investigator, would render vaccination unsafe or interfere with the evaluation of response. - use of experimental vaccines or medications within 30 days of study entry; - receipt of parenteral immunoglobulin within 60 days of study entry; - all women who will be pregnant during the influenza season; - residents of nursing homes and long-term care facilities; - health-care workers involved in direct patient care and included in DOD priority 1; and; - military recruits; - out-of-home caregivers and household contacts of children aged <6 months. - Anyone with clinical contraindications for receiving the inactivated influenza vaccine such as a history of severe allergic reaction to prior influenza vaccinations, severe allergy to egg and/or egg proteins and gelatin. - DOD Priority 1: Deployed or deploying (with orders) service members and others designated as critical to national defense. - DOD Priority 2: Medically high risk in accordance with ACIP guidelines (includes health-care workers with direct patient contact) - Any acute or chronic condition that, in the opinion of the investigator or her provider designee would render vaccination unsafe or interfere with the evaluation of the response. |
Country | Name | City | State |
---|---|---|---|
United States | Pentagon | Washington | District of Columbia |
United States | Walter Reed Army Medical Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
U.S. Army Medical Research and Development Command | Centers for Disease Control and Prevention, U.S. Air Force Office of the Surgeon General, Uniformed Services University of the Health Sciences, United States Army Medical Materiel Development Activity, Walter Reed Army Institute of Research (WRAIR), Walter Reed Army Medical Center |
United States,
Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, Treanor JJ; Walter Reed Health Care System Influenza Vaccine Consortium. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, d — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Race/Ethnicity Baseline Measure | Race/ethnicity data was only collected by age and cannot be separated out by dose as per the other Baseline Measures | Enrollment Day | |
Primary | Immune Response: Age 18-49 | Immune response as measured by viral strain specific hemaggluttination inhibition (HAI) antibody levels for subjects ages 18-49 | 21 days post-vaccincation | |
Primary | Immune Response: Age 50-64 | Immune response as measured by viral strain specific hemaggluttination inhibition (HAI) antibody levels for subjects ages 50-64 | 21 days post-vaccincation | |
Secondary | Medical Events: Unsolicited Adverse Events | Assessed through following subjects' recording of oral body temperature, completion of a 21-day symptom diary; subjects' completion of longer-term follow-up surveys to track respiratory symptoms; and a review of the Defense Medical Surveillance System (DMSS) hospitalization and outpatient medical visits database in order to track ICD-9 codes relevant to flu-like illness. | 3 - 6 months following vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |